Yan Xiaoyu 閆曉宇
School of Pharmacy
Faculty of Medicine
The Chinese University of Hong Kong
Tel: (852) 3943 5012
Fax:(852) 2603 5295
Xiaoyu Yan received his Bachelor’s and Master’s degree from Shenyang Pharmaceutical University, China. He also received a Master’s degree in pharmaceutical sciences from University of Saskatchewan, Canada. He obtained his PhD in 2012 from Department of Pharmaceutical Sciences, University at Buffalo (SUNY). After his PhD, he worked as a clinical pharmacometrician/pharmacologist at Janssen Research & Development (Johnson & Johnson) and Regeneron Pharmaceuticals, USA.
During his time in pharmaceutical industry, Xiaoyu applied model informed drug development approaches to help the development team not only better understand disease and target, but also find the right dose for the right patient at right time. He has contributed to the global approval of several new therapies for diseases in various areas, such as oncology, immunology, cardiovascular, and neuroscience.
Xiaoyu joined the School of Pharmacy at the Chinese University of Hong Kong in September 2018. His research interests are focused on the pharmacokinetics and pharmacodynamics of therapeutic biologics, and utilization of modeling and simulation approaches to optimize drug therapy and develop new treatment strategy.
***Xiaoyu’s group has openings for postdoctoral fellows, MPhil/PhD students, research assistants, visiting scholars. Candidates with a background in relative areas (biochemistry/molecular biology, pharmacology, cell biology, immunology, biochemical engineering, drug metabolism and pharmacokinetics, mathematics, statistics or other field related) are welcome to apply. Please contact Dr. Yan (email@example.com) for more information.***
Xiaoyu’s current research is focused on the development of new therapies for anemic patients demonstrating resistance to erythropoiesis-stimulating agents (ESAs). ESAs is a class of therapeutic proteins functioning as erythropoietin receptor (EPOR) agonists. They stimulate the production of red blood cells by binding to EPOR on erythroid cells in bone marrow, and stimulate their proliferation and differentiation.
ESAs has transformed the way of managing the anemia in patients with chronic kidney disease (CKD), who may need blood transfusion otherwise. Recombinant human erythropoietin (rHuEPO) is the first approved ESA by US FDA in 1989 to treat anemia associated with CKD. However, up to 10% of anemic patients failed to show a satisfactory response to rHuEPO, and still require blood transfusion eventually. This phenomenon was named EPO resistance. The EPO resistance is also associated with increased risk of death or cardiovascular events.
Xiaoyu’s previous work suggested the rHuEPO treatment can induce erythroid precursor pool depletion, which may contribute to EPO resistance. Accordingly, his current work is to further the understanding role of precursor depletion in EPO resistance, and look for new therapeutic strategy that may alleviate rHuEPO induced precursor depletion. This work may provide new treatment option for anemic patients showing EPO resistance, and reduce their transfusion burden.
- PHAR5130 Overview of Drug Development
- PHAR2220 Biopharmaceutics and Pharmacokinetics
- GENA1113 General Education
(* Corresponding author)
- Zou H, Banerjee P, Leung SSY, Yan X*. Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. Front. Pharmacol., 03 July 2020
- Yan X*, Xu SX*, Weisel KC, et al. Early M-protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Clinical and Translational Science. June 2020
- Zhang L, Yan X, Nandy P, Willmann S, Fox KAA, Berkowitz SD, Sharma A, Hermanowski-Vosatka A, Schmidt S, Weitz JI, Garmann D, Peters G. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation J Thromb Thrombolysis. 2020 Apr 23
- Yan X*, Ruixo JJP, Krzyzanski W. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens. AAPS J. 2020 Jan 16;22(2):30
- Zhang L, Yan X, Nandy P, Willmann S, Fox KAA, Berkowitz SD, Sharma A, Hermanowski-Vosatka A, Schmidt S, Weitz JI, Garmann D, Peters G. Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. Ther Adv Cardiovasc Dis 2020; Jan
- Solms A, Frede M, Berkowitz SD, Hermanowski-Vosatka A, Kubitza D, Mueck W, Spiro TE, Willmann S, Yan X, Zhang L, Garmann D. Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. CPT Pharmacometrics Syst Pharmacol 2019;8(11):805-14
- D’Cunha R, Schmidt R, Widness JA, Mock DM, Yan X, Cress GA, Kuruvilla D, Veng-Pedersen P, An G. Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens. Eur J Pharm Sci. 2019; 138:105013.
- Zhang Y, Lyu C, Fong S, Wang Q, Li C, Ho NJ, Chan KS, Yan X, Zuo Z. Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs. J Ethnopharmacol. 2019: Jul 17:112097
- Ren T, Xiao M, Yang M, Zhao J, Zhang Y, Hu M, Cheng Y, Xu H, Zhang C, Yan X, Zuo Z. Reduced Systemic and Brain Exposure with Inhibited Liver Metabolism of Carbamazepine After Its Long-Term Combination Treatment with Piperine for Epilepsy Control in Rats. AAPS J. 2019;21(5):90.
- D’Cunha R, Widness JA, Yan X, Schmidt RL, Veng-Pedersen P, An G. A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses. J Clin Pharmacol. 2019 59(6):835-846
- Janssen R&D, Innovation Leadership Awards, 2016
- Janssen R&D, Innovation Leadership Awards, 2015
- Janssen R&D, Innovation Leadership Awards, 2014
- McKeen Cattell Memorial Award, American College of Clinical Pharmacology (ACCP) Recognition Award, Washington, DC 2013
- American Society for Clinical Pharmacology & Therapeutics (ASCPT) Presidential Trainee Award, ASCPT Annual Meeting, Indianapolis, IN 2013
- Graduate Student Symposium Award PPDM/CPTR, American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Washington, DC, 2011
- Travel Award by AAPS Executive Council, AAPS Annual Meeting, New Orleans, LA, 2010
- Pfizer Canada Centennial Pharmacy Research Award, Saskatoon, Canada 2006
- American Association of Pharmaceutical Scientists
- American College of Clinical Pharmacology
- International Society of Pharmacometrics (ISoP)
- American Society Clinical Pharmacology & Therapeutics